Form 4: DURECT Director Reports Merger-Related Stock Changes

DURECT Director Mohammad Azab disposed of common stock and stock options as part of the company's merger with Bausch Health Americas, Inc. for $1.75 cash per share plus contingent value rights.

Summary

• Director Mohammad Azab reported changes in beneficial ownership due to the merger of DURECT Corporation with Bausch Health Americas, Inc. (Parent) and BHC Lyon Merger Sub, Inc. (Purchaser).
• The merger became effective on September 11, 2025, with DURECT continuing as a wholly-owned subsidiary of Parent.
• Common stockholders received $1.75 per share in cash, plus one non-tradeable contingent value right (CVR) per share.
• CVRs represent a pro rata share of up to $350,000,000 in aggregate milestone payments, contingent on achieving specified net sales milestones.
• Stock options with an exercise price less than $1.75 were accelerated, and the resulting shares were treated identically to other common stock in the tender offer and merger.
• Stock options with an exercise price equal to or greater than $1.75 were canceled at the effective time of the merger.
• Former holders of canceled options are eligible for a cash retention bonus subject to the achievement of certain net sales milestones.
• Mohammad Azab disposed of 6,000 shares of common stock and various stock options on September 11, 2025, resulting in zero beneficially owned shares or derivative securities following the transactions.

Sentiment

Score: 7

Explanation: The filing details the successful completion of a merger, providing a clear exit for shareholders with a cash component and potential upside via CVRs. While some options were canceled, a retention plan is in place. This represents a definitive strategic outcome for the company.

Positives

• The merger provides a clear exit strategy for DURECT shareholders, offering immediate cash consideration of $1.75 per share.
• Contingent Value Rights (CVRs) offer potential upside for shareholders if specified milestones are met, providing a mechanism to participate in future success.
• A retention plan for option holders with higher exercise prices aims to incentivize key personnel post-merger, aligning their interests with future performance.

Negatives

• Stock options with exercise prices equal to or greater than $1.75 were canceled, meaning these options did not yield direct value from the tender offer.
• CVRs are non-tradeable, limiting liquidity and immediate valuation, with their value entirely dependent on future milestone achievement.
• The cash consideration of $1.75 per share might be lower than previous trading prices or perceived intrinsic value for some investors.

Risks

• Achievement of milestone payments for CVRs is uncertain and dependent on future net sales, which may not materialize.
• The value of the retention bonuses for canceled options is also contingent on achieving certain net sales milestones, introducing performance risk.
• Integration risks are inherent with DURECT becoming a wholly-owned subsidiary of Bausch Health Americas, Inc.

Future Outlook

DURECT Corporation will continue as a wholly-owned subsidiary of Bausch Health Americas, Inc. The future value for former DURECT shareholders holding CVRs is tied to the achievement of specified net sales milestones. A retention plan is in place for certain option holders, also contingent on net sales milestones.

Management Comments

• Tendering stockholders received a consideration of $1.75 per share, net to the seller of such shares in cash, without interest thereon and less any applicable withholding taxes (the 'Cash Amount'), plus one non-tradeable contingent value right per share, representing the contractual right to receive the pro rata portion, in cash, of two milestone payments of up to $350,000,000 in the aggregate.
• At the Effective Time, each Issuer Option that had a per share exercise price that was equal to or greater than the Cash Amount, and that was unexercised immediately prior to the Effective Time, was canceled in connection with the Merger. Following the cancellation of each such Issuer Option, each former holder of such Issuer Option is eligible to receive a cash retention bonus subject to the achievement of certain net sales milestones.

Industry Context

This filing reflects a common trend of larger pharmaceutical or healthcare companies acquiring smaller biotech firms, often to gain access to specific drug pipelines or technologies. The use of CVRs is a strategy to bridge valuation gaps and share future risks/rewards, particularly common in biotech acquisitions where product success is uncertain.

Comparison to Industry Standards

• The use of Contingent Value Rights (CVRs) in biotech acquisitions is a standard practice, seen in deals like Sanofi's acquisition of Kadmon Holdings or Bristol Myers Squibb's acquisition of MyoKardia. These structures allow buyers to mitigate risk on unproven assets while offering sellers potential upside.
• The cash component of $1.75 per share, combined with CVRs, is a typical structure for such transactions, balancing immediate liquidity with future performance incentives.
• Retention plans for key personnel, especially those with 'out-of-the-money' options, are standard to ensure continuity and motivation post-acquisition.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received $1.75 cash per share plus CVRs, providing immediate liquidity and potential future upside.
• Employees/Option Holders: Those with in-the-money options likely benefited from acceleration and tender. Those with out-of-the-money options had them canceled but are eligible for retention bonuses tied to performance.
• Company (DURECT): Now operates as a wholly-owned subsidiary, losing its independent public status.
• Bausch Health Americas, Inc.: Successfully acquired DURECT, expanding its portfolio.

Next Steps

• Former DURECT shareholders holding CVRs will await the achievement of specified net sales milestones for potential future payments.
• Eligible former option holders will await the achievement of net sales milestones for cash retention bonuses.
• DURECT Corporation will operate as a wholly-owned subsidiary of Bausch Health Americas, Inc.

Key Dates

Keywords

DURECT, DRRX, Bausch Health, Merger, Acquisition, Contingent Value Right, CVR, Stock Options, Tender Offer, SEC Form 4, Mohammad Azab, Corporate Governance